MyFinsight
Home
Blog
About
Citius Pharmaceuticals, Inc. (CTXR)
Citius Pharmaceuticals, Inc. (CTXR)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Unit: Dollar
Positive Cash Flow Breakdown
Proceeds from exercise of warran...
Net proceeds from loan agreement
Net proceeds from common stock o...
Others
Negative Cash Flow Breakdown
Net loss
License fee payments
Accrued compensation
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-11,919,260
-28,109,746
-9,393,889
-8,743,646
Stock-based compensation expense
3,810,665
3,788,275
4,280,227
2,889,762
Issuance of common stock for services
0
0
107,510
26,600
Issuance of common stock warrant
0
0
68,597
-
Amortization of in-process research and development
1,720,312
1,720,312
573,438
-
Amortization of operating lease right-of-use asset
41,479
40,659
-16,483
62,038
Amortization of deferred financing costs
179,492
-
-
-
Deferred income tax expense (benefit)
-107,347
-231,210
264,240
264,240
Accounts receivable, net of allowances
-392,820
-2,970,056
4,049,111
-
Inventory
-33,645
20,248
352,649
3,709,006
Prepaid expenses
-345,222
-178,405
2,139,797
1,451,034
Accounts payable
-1,415,904
-1,567,609
-2,672,280
3,599,650
Accrued expenses
13,198
19,444,957
503,054
-4,333,422
Accrued compensation
-1,730,687
507,612
-198,052
-417,594
Operating lease liability
-41,205
-21,484
16,373
-68,378
Net cash used in operating activities
-8,677,570
-1,300,021
-13,008,822
-11,880,790
License fee payments
2,000,000
600,000
4,400,000
5,750,000
Net cash used in investing activities
-2,000,000
-600,000
-4,400,000
-5,750,000
Proceeds from (repayment of) note payable and advance from employee
-1,000,000
-
-
-
Net proceeds from loan agreement
9,635,000
-
-
-
Proceeds from note payable and advance from employee
-
-
-
0
Repayment of note payable
-
1,000,000
-
-
Proceeds from exercise of warrants
9,730,285
818
-
-
Repayment of advance from employee
-
-
-
0
Deferred financing costs
723,299
169,252
-
-
Net proceeds from common stock offerings
4,452,933
-62,764
20,877,925
15,793,954
Net cash provided by financing activities
23,094,919
-1,231,198
20,877,925
15,793,954
Net change in cash and cash equivalents
12,417,349
-3,131,219
3,469,103
-1,836,836
Cash and cash equivalents - beginning of period
7,721,393
7,721,393
4,252,290
3,251,880
Cash and cash equivalents - end of period
17,007,523
4,590,174
7,721,393
4,252,290
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from exercise of
warrants
$9,730,285
Net proceeds from
loan agreement
$9,635,000
Net proceeds from
common stock offerings
$4,452,933
(-73.03%↓ Y/Y)
Net cash provided by
financing activities
$23,094,919
(31.90%↑ Y/Y)
Canceled cashflow
$1,723,299
Net change in cash
and cash...
$12,417,349
(337.66%↑ Y/Y)
Canceled cashflow
$10,677,570
Proceeds from (repayment
of) note payable and...
-$1,000,000
Deferred financing costs
$723,299
Stock-based compensation
expense
$3,810,665
(-52.05%↓ Y/Y)
Amortization of in-process
research and development
$1,720,312
Accounts receivable, net
of allowances
-$392,820
Prepaid expenses
-$345,222
(75.11%↑ Y/Y)
Amortization of deferred
financing costs
$179,492
Amortization of operating
lease right-of-use...
$41,479
(-72.75%↓ Y/Y)
Inventory
-$33,645
(-100.38%↓ Y/Y)
Accrued expenses
$13,198
(-99.84%↓ Y/Y)
Net cash used in
operating activities
-$8,677,570
(40.86%↑ Y/Y)
Net cash used in
investing activities
-$2,000,000
Canceled cashflow
$6,536,833
Net loss
-$11,919,260
(61.55%↑ Y/Y)
License fee payments
$2,000,000
Accrued compensation
-$1,730,687
(-216.86%↓ Y/Y)
Accounts payable
-$1,415,904
(-127.40%↓ Y/Y)
Deferred income tax
expense (benefit)
-$107,347
(-113.54%↓ Y/Y)
Operating lease liability
-$41,205
(75.46%↑ Y/Y)
Buy us a coffee